




RealRate

PHARMACEUTICAL 2023

Cartesian Therapeutics Inc
Rank 172 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Cartesian Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cartesian Therapeutics Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 82% points. The greatest weakness of Cartesian Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 304%, being 59% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	148,138
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	25,077
Liabilities, Non-Current	10,055
Other Assets	14,954
Other Compr. Net Income	8.0
Other Expenses	-18,460
Other Liabilities	36,926
Other Net Income	2,381
Other Revenues	110,777
Property and Equipment	2,794
Research and Development	72,377
Selling, General and Administrative Expense	23,862

Output Variable	Value in 1000 USD
Assets	165,886
Liabilities	72,058
Expenses	77,779
Revenues	110,777
Stockholders Equity	93,828
Net Income	35,379
Comprehensive Net Income	35,383
BaseVar	214,444
ECR before LimitedLiability	202%
Economic Capital Ratio	304%